التداخل بين ليثيوم وفيراباميل

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus.

Lithium Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.

However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.